Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
31 hedge funds and large institutions have $61.3M invested in Fusion Pharmaceuticals Inc. Common Shares in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
11% more funds holding
Funds holding: 28 → 31 (+3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
72% less capital invested
Capital invested by funds: $219M → $61.3M (-$158M)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$317K |
| 2 |
Millennium Management
New York
|
+$53.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$15K |
| 4 |
HFS
Heritage Financial Services
Westwood,
Massachusetts
|
+$4.59K |
| 5 |
SCM
Sio Capital Management
New York
|
+$3.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$802K |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$636K |
| 3 |
Morgan Stanley
New York
|
-$208K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$200K |
| 5 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$172K |
FUSN Hedge Fund Activity: Q2 2022 in Review
31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2022, worth a combined $61.3M — down 72% from $219M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new FUSN positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 8 trimmed.
The largest buyer was Federated Hermes, adding an estimated $317K. The largest seller was Perceptive Advisors, cutting an estimated $802K.
- 31 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2022, up from 28 in Q1 2022.
- Funds reported $61.3M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2022, down 72% quarter-over-quarter.
- 4 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2022 and 1 closed out, a net change of +3 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2022 was Federated Hermes, an estimated $317K added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2022 was Perceptive Advisors, an estimated $802K sold.
Based on aggregated 13F filings for Q2 2022.